Predicting upper price targets for Aquestive Therapeutics involves analyzing future commercialization milestones, potential regulatory approvals for its pipeline products, and broader market liquidity. Equity research analysts and algorithmic forecasting platforms construct varied price projections based on successful drug delivery approvals and commercial adoption rates. However, because small-cap biopharma stocks carry unpredictable trajectories dependent on upcoming regulatory catalysts, targets can shift dramatically depending on execution success.